Perioperative Complications in Reversed Shoulder Arthroplasties

Perioperative Complications in Proximal Humeral Fractures Treated With Reversed Shoulder Arthroplasties

Retrospective observational study of reversed shoulder arthroplasties by proximal humeral fracture. Analysis of preoperative risk factors as well as minor and major complications at the first week, 90 days and 1 year.

Study Overview

Status

Unknown

Detailed Description

The study is a multicenter retrospective observational study (3 centers). Data are collected from 105 patients over 65 years-old undergoing reversed shoulder arthroplasties by proximal humerus fractures, in 3 or 4 parts.

Patient information is obtained from the clinical records in their usual preoperative assessment, and follow-up on the usual routine checks, at the first week, 90 days and 1 year.

Minor and major complications rates are evaluated according to preoperative risk (ASA), underlying diseases and according to anticoagulant / antiaggregant treatments.

Likewise, transfusion rates related to ASA, as well as length of hospital stay related to it.

Study Type

Observational

Enrollment (Anticipated)

105

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Barcelona, Spain, 08025
        • Recruiting
        • Hospital de La Santa Creu I Sant Pau
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years and older (Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients undergoing reversed shoulder arthroplasties owing to three or four parts fractures of the proximal humerus

Description

Inclusion Criteria:

  • Complex( 3- or 4-part) humerus fractures undergoing reversed shoulder arthroplasties.

Exclusion Criteria:

  • No exclusion criteria

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Retrospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of patients affected by minor complications according to preoperative risk (ASA) in reversed shoulder arthroplasties due to complex proximal humeral fractures.
Time Frame: First week after surgery
Minor complications are medical complications, which usually don't affect to the functional outcome of arthroplasties
First week after surgery
Number of patients affected by minor complications according to preoperative risk (ASA) in reversed shoulder arthroplasties due to complex proximal humeral fractures.
Time Frame: 90 days after surgery
Minor complications are medical complications, which usually don't affect to the functional outcome of arthroplasties
90 days after surgery
Number of patients affected by minor complications according to preoperative risk (ASA) in reversed shoulder arthroplasties due to complex proximal humeral fractures.
Time Frame: 1 year after surgery
Minor complications are medical complications, which usually don't affect to the functional outcome of arthroplasties
1 year after surgery
Number of patients affected by major complications according to preoperative risk (ASA) in reversed shoulder arthroplasties due to complex proximal humeral fractures.
Time Frame: First week after surgery
Major complications are surgical complications( dislocation, periprosthetic fracture, infection) which usually affect to the functional outcome and can lead to a revision surgery
First week after surgery
Number of patients affected by major complications according to preoperative risk (ASA) in reversed shoulder arthroplasties due to complex proximal humeral fractures.
Time Frame: 90 days after surgery
Major complications are surgical complications( dislocation, periprosthetic fracture, infection) which usually affect to the functional outcome and can lead to a revision surgery
90 days after surgery
Number of patients affected by major complications according to preoperative risk (ASA) in reversed shoulder arthroplasties due to complex proximal humeral fractures.
Time Frame: 1 year after surgery
Major complications are surgical complications( dislocation, periprosthetic fracture, infection) which usually affect to the functional outcome and can lead to a revision surgery
1 year after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of patients affected by minor complications after surgery, according to underlying disease
Time Frame: First week after surgery
Underlying diseases group: cardiovascular, neurological, rheumatic, psychiatric, neoplasic.
First week after surgery
Number of patients with cardiovascular diseases affected by minor complications after surgery
Time Frame: 90 days after surgery
Underlying diseases group: cardiovascular, neurological, rheumatic, psychiatric, neoplasic.
90 days after surgery
Number of patients with cardiovascular diseases affected by minor complications after surgery
Time Frame: 1 year after surgery
Underlying diseases group: cardiovascular, neurological, rheumatic, psychiatric, neoplasic.
1 year after surgery
Number of patients with cardiovascular diseases affected by major complications after surgery
Time Frame: First week after surgery
Underlying diseases group: cardiovascular, neurological, rheumatic, psychiatric, neoplasic.
First week after surgery
Number of patients with cardiovascular diseases affected by major complications after surgery
Time Frame: 90 days after surgery
Underlying diseases group: cardiovascular, neurological, rheumatic, psychiatric, neoplasic.
90 days after surgery
Number of patients with cardiovascular diseases affected by major complications after surgery
Time Frame: 1 year after surgery
Underlying diseases group: cardiovascular, neurological, rheumatic, psychiatric, neoplasic.
1 year after surgery
Number of patients undergoing anticoagulant treatment with minor complications
Time Frame: First week after surgery
Previous acenocoumarol treatment
First week after surgery
Number of patients undergoing anticoagulant treatment with major complications
Time Frame: First week after surgery
Previous acenocoumarol treatment
First week after surgery
Number of patients undergoing anticoagulant treatment with minor complications
Time Frame: 90 days after surgery
Previous acenocoumarol treatment
90 days after surgery
Number of patients undergoing anticoagulant treatment with major complications
Time Frame: 90 days after surgery
Previous acenocoumarol treatment
90 days after surgery
Number of patients undergoing antiplatelet treatment with minor complications
Time Frame: First week after surgery
Previous Acetylsalicylic acid (Aspirin), triflusal, ticlopidine, clopidogrel or prasugrel
First week after surgery
Number of patients undergoing antiplatelet treatment with major complications
Time Frame: First week after surgery
Previous Acetylsalicylic acid (Aspirin), triflusal, ticlopidine, clopidogrel or prasugrel
First week after surgery
Number of patients undergoing antiplatelet treatment with minor complications
Time Frame: 90 days after surgery
Previous Acetylsalicylic acid (Aspirin), triflusal, ticlopidine, clopidogrel or prasugrel
90 days after surgery
Number of patients undergoing antiplatelet treatment with major complications
Time Frame: 90 days after surgery
Previous Acetylsalicylic acid (Aspirin), triflusal, ticlopidine, clopidogrel or prasugrel
90 days after surgery
Transfusion rates according to the preoperative ASA group
Time Frame: 1 week after surgery
Number of transfusion requirement.
1 week after surgery
Length of hospital stay according to the preoperative ASA group
Time Frame: 1 week after surgery
Length from the surgical intervention according to ASA risk
1 week after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Carles Torrens Canovas, Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 25, 2017

Primary Completion (Anticipated)

August 31, 2017

Study Completion (Anticipated)

August 31, 2017

Study Registration Dates

First Submitted

July 31, 2017

First Submitted That Met QC Criteria

August 3, 2017

First Posted (Actual)

August 9, 2017

Study Record Updates

Last Update Posted (Actual)

August 9, 2017

Last Update Submitted That Met QC Criteria

August 3, 2017

Last Verified

August 1, 2017

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Proximal Humeral Fracture

3
Subscribe